PharVision Advisers LLC Acquires New Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

PharVision Advisers LLC bought a new stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 21,895 shares of the medical technology company's stock, valued at approximately $201,000.

Other large investors have also recently made changes to their positions in the company. Comerica Bank grew its holdings in Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after buying an additional 1,248 shares during the last quarter. R Squared Ltd acquired a new position in Alphatec in the fourth quarter valued at approximately $29,000. Nisa Investment Advisors LLC boosted its position in shares of Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after buying an additional 4,234 shares during the period. Quarry LP raised its holdings in Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after purchasing an additional 2,375 shares in the last quarter. Finally, Newton One Investments LLC purchased a new stake in shares of Alphatec in the fourth quarter valued at $50,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Price Performance

Shares of NASDAQ:ATEC traded down $0.02 on Thursday, hitting $12.42. The stock had a trading volume of 245,765 shares, compared to its average volume of 2,036,884. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -9.66 and a beta of 1.06. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The firm's 50 day moving average price is $11.21 and its 200-day moving average price is $10.59. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $13.14.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). The business had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm's revenue was up 22.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.34) earnings per share. On average, equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Insider Buying and Selling at Alphatec

In related news, CEO Patrick Miles sold 12,691 shares of Alphatec stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the transaction, the chief executive officer now owns 5,857,603 shares of the company's stock, valued at $62,324,895.92. This trade represents a 0.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Scott Lish sold 55,375 shares of Alphatec stock in a transaction on Monday, May 19th. The stock was sold at an average price of $13.00, for a total transaction of $719,875.00. Following the transaction, the chief operating officer now directly owns 771,645 shares in the company, valued at approximately $10,031,385. This represents a 6.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 113,798 shares of company stock valued at $1,365,665. 20.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on ATEC shares. Wall Street Zen raised shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Piper Sandler reiterated an "overweight" rating and set a $15.00 target price (up from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $17.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.